MX2022007464A - Composiciones biofarmaceuticas y metodos relacionados. - Google Patents

Composiciones biofarmaceuticas y metodos relacionados.

Info

Publication number
MX2022007464A
MX2022007464A MX2022007464A MX2022007464A MX2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A MX 2022007464 A MX2022007464 A MX 2022007464A
Authority
MX
Mexico
Prior art keywords
related methods
biopharmaceutical compositions
compositions
biopharmaceutical
antagonism
Prior art date
Application number
MX2022007464A
Other languages
English (en)
Inventor
Kelly Neelon
Mingxuan Zhang
Original Assignee
Tesaro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tesaro Inc filed Critical Tesaro Inc
Publication of MX2022007464A publication Critical patent/MX2022007464A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere

Abstract

La invención descrita en la presente proporciona composiciones que comprenden anticuerpos anti-PD-1 y métodos relacionados para tratar el cáncer y otros trastornos que responden al antagonismo de PD-1.
MX2022007464A 2019-12-18 2020-12-10 Composiciones biofarmaceuticas y metodos relacionados. MX2022007464A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962949696P 2019-12-18 2019-12-18
US201962950595P 2019-12-19 2019-12-19
PCT/US2020/064241 WO2021126657A1 (en) 2019-12-18 2020-12-10 Biopharmaceutical compositions and related methods

Publications (1)

Publication Number Publication Date
MX2022007464A true MX2022007464A (es) 2022-06-27

Family

ID=74125707

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022007464A MX2022007464A (es) 2019-12-18 2020-12-10 Composiciones biofarmaceuticas y metodos relacionados.

Country Status (11)

Country Link
US (1) US20230059341A1 (es)
EP (1) EP4077388A1 (es)
JP (1) JP2023507981A (es)
KR (1) KR20220129548A (es)
CN (1) CN115298218A (es)
AU (1) AU2020407007A1 (es)
BR (1) BR112022014694A2 (es)
CA (1) CA3164600A1 (es)
IL (1) IL293753A (es)
MX (1) MX2022007464A (es)
WO (1) WO2021126657A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2899308C (en) * 2013-03-14 2017-04-18 Abbvie Inc. Low acidic species adalimumab compositions and uses thereof
MX2015015037A (es) 2013-05-02 2016-07-08 Anaptysbio Inc Anticuerpos dirigidos contra la proteina muerte programada-1 (pd-1).
MA41463A (fr) 2015-02-03 2017-12-12 Anaptysbio Inc Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3)
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
MA42692A (fr) * 2015-08-24 2018-07-04 Glaxosmithkline Ip No 2 Ltd Compositions biopharmaceutiques
SG11201903835WA (en) 2016-11-01 2019-05-30 Anaptysbio Inc Antibodies directed against programmed death- 1 (pd-1)
WO2018129559A1 (en) 2017-01-09 2018-07-12 Tesaro, Inc. Methods of treating cancer with anti-pd-1 antibodies
JOP20190260A1 (ar) * 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها

Also Published As

Publication number Publication date
IL293753A (en) 2022-08-01
EP4077388A1 (en) 2022-10-26
WO2021126657A1 (en) 2021-06-24
BR112022014694A2 (pt) 2022-09-06
AU2020407007A1 (en) 2022-06-23
KR20220129548A (ko) 2022-09-23
CN115298218A (zh) 2022-11-04
JP2023507981A (ja) 2023-02-28
CA3164600A1 (en) 2021-06-24
US20230059341A1 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
ZA201801852B (en) Anti¿pd¿1 antibodies and compositions
AU2018263868A1 (en) Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
WO2018069500A3 (en) ANTI-LAG-3 ANTIBODIES AND COMPOSITIONS
MX2018016364A (es) Anticuerpos anti-pd-l1.
PH12018502225A1 (en) Anti-il-33 antibodies, compositions, methods and uses thereof
PH12019500923A1 (en) Anti-pd-1 antibodies and compositions
PH12018501268A1 (en) Compounds useful as kinase inhibitors
PH12020551463A1 (en) Pd-1 agonist antibodies and uses thereof.
NZ766356A (en) Anti-pd-1 antibodies
CR20210500A (es) Anticuerpos de cadena pesada que se unen al psma
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
MX2019001471A (es) Anticuerpos anti-siglec-7 para el tratamiento del cancer.
WO2020051333A8 (en) Anti-avb8 antibodies and compositions and uses thereof
PH12020500576A1 (en) Method of treating cancers with antagonistic anti-pd-1 antibodies
MX2019009772A (es) Anticuerpos anti-pd-1 para el tratamiento del cancer de pulmon.
PH12019501872A1 (en) Anti-tryptase antibodies, compositions thereof, and uses thereof
CR20210622A (es) Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
WO2017122098A3 (en) Anti pd-l antibodies for enhancing the potency of superantigen mediated cancer immunotherapy
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2022002682A (es) Anticuerpos anti-cd73.
WO2018087143A3 (en) Anti-pd-1 antibodies
AU2018279184A1 (en) Anti-TrkB antibodies
MX2021003888A (es) Nuevos compuestos utiles para el tratamiento de enfermedades cardiovasculares.